BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38562027)

  • 21. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
    Zipori AB; Tehrani NN; Ali A
    J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile.
    Trelińska J; Dachowska I; Kotulska K; Jóźwiak S; Fendler W; Młynarski W
    Pharmacol Rep; 2016 Oct; 68(5):1002-7. PubMed ID: 27423526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
    Ichikawa T; Niida Y
    No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
    Kotulska K; Borkowska J; Mandera M; Roszkowski M; Jurkiewicz E; Grajkowska W; Bilska M; Jóźwiak S
    Childs Nerv Syst; 2014 Dec; 30(12):2037-42. PubMed ID: 25227171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
    Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
    Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
    Cheng S; Hawkins C; Taylor MD; Bartels U
    Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP
    Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
    J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
    Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
    Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures.
    Kuzniewska B; Sadowski K; Urbanska K; Urbanska M; Kotulska K; Liszewska E; Grajkowska W; Jóźwiak S; Dziembowska M
    Folia Neuropathol; 2018; 56(3):167-174. PubMed ID: 30509037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
    Lechuga L; Franz DN
    Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
    [No Abstract]   [Full Text] [Related]  

  • 40. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.